Ecthyma (ICD-9 code 686.8)
Are You Confident of the Diagnosis?
Characteristic findings on physical examination
Ecthyma is an ulcerative infection of the skin, caused by group-A beta-hemolytic streptococci. In its earliest stage, ecthyma may present in a similar fashion to impetigo. Lesions of ecthyma may result from primary infection, or from secondary infection of other lesions or wounds. There are usually less than ten lesions present (
Ecthyma on dorsal hand of 55-year old-alcoholic who presented to the emergency room (Courtesy of Chad Hivnor, MD)
Ecthyma usually begins as a small vesicle or pustule. Over the period of several days, theses lesions increase in size and form an overlying crust. The ulcer appears shallow and punched-out when the crust is removed. Ecthyma heals slowly, and residual scarring is left. Regional lymphadenopathy is common, while systemic symptoms, cellulitis, and osteomyelitis is very infrequent.
Gram stain and culture may be used for micrbiologic confirmation. The differential diagnosis includes ecthyma gangrenosum, insect bites, pyoderma gangenosum, and infections which cause ulcerative lesions. These infections include entities such as sporotrichosis, leishmaniasis, Mycobacterium marinum, and deep fungal infections to differentiate the infections, culture and biopsies would be indicated.
Who is at Risk for Developing this Disease?
Individuals with immunosuppressive conditions are at higher risk for ecthyma, as are those with preexisting dermatoses or wounds. Individuals with areas of skin injury also have a higher risk. Poor hygiene, crowded conditions, and high temperature and humidity are other risk factors. There is no racial or sexual predisposition.
What is the Cause of the Disease?
As noted above, streptococci usually initiate the disease. Staphylococci may contaminate these lesions once they form.
Systemic Implications and Complications
Systemic complications, including cellulitis, osteomyelitis, and bacteremia, are very rare.
Treatment options are summarized in
Treatment options for ecthyma
|Mupirocin or retapamulin ointment||Oral penicillin/antistaphylococcal antibiotics (cephalexin 250mg po four times a day; penicillin VK 0.25-0.5g po four times a day; Clindamycin 150-300 mg po four times a day||Debride ecthyma crusts|
|Intravenous antibiotics with coverage for streptococci/staphylococci (clindamycin 600–1200mg/day in 2, 3 or 4 equal doses; cephalexin 500mg-1g every 12 hours)|
Optimal Therapeutic Approach for this Disease
Topical therapy for mupurocin ointment may be considered for localized disease. In terms or oral therapy, ecthyma caused by streptococci can be adequately treated with a 10-day course of an antibiotic with Gram-positive activity, such as cephalexin or dicloxicillin. In the event of secondary stapylococcal involvement, therapy should be based on microbiologic findings. For more widespread involvement, intravenous antibiotics, including such drugss clindamycin, oxacillin, and vancomycin, should be considered.
The prognosis is favorable. As above, lesions heal slowly over several weeks. Avoiding predisposing factors may be warranted to reduce recurrence. The patient should be monitored closely, with follow-up within 1 week after presentation, or sooner if the condition warrants
Unusual Clinical Scenarios to Consider in Patient Management
Patients with a history of immunosuppression or with other comorbidites should be monitored closely. Ecthyma gangrenosum, which is in the differential diagnosis of ecthyma, is associated with a Pseudomonas aeruginosa bacteremia. This entity usually occurs in patients who are critically ill and immunocompromised.
What is the Evidence?
Wasserzug, O, Valinsky, L, Klement, E. "A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes". Clin Infect Dis. vol. 48. 2009. pp. 1213-9.(This study demonstrates the possible ramifications of the combination of a virulent and highly infective S. pyogenes strain and poor living conditions, and it emphasizes the importance of early intervention in such conditions.)
Martin, JM, Green, M. "Group A streptococcus". Semin Pediatr Infect Dis. vol. 17. 2006. pp. 140-8.(The article reviews the manifestations of group A streptococci (GAS). Infections due to GAS include pharyngitis, impetigo, ecthyma, erysipelas, and cellulitis. These infections, as well as the manifestations of invasive disease including streptococcal toxic shock syndrome and necrotizing fasciitis, are reviewed in this article.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|